Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

About this update from Zhengye Biotechnology Holding Limited

Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Company’s research and operational milestones achieved in 2025 and outlines Zhengye’s strategic priorities for growth in 2026. The full text of the letter follows. Dear Shareholders, As we enter 2026, on behalf of the management of Zhengye Biotechnology Holding Limited, I am proud of the milestones we achieved in 2025 and would like to share our strategic vision for 2026 and the years ahead. In 2025, China’s swine industry continued to consolidate, with large-scale producers gaining market share and raising standards for vaccine quality and technical service. In response, Zhengye strengthened its research and development (“R&D”) activities, achieved regulatory milestones, and strengthened its operational platforms. I am deeply encouraged by what our team accomplished. The milestones we achieved are not just metrics on paper—I believe they represent real competitive advantages that position us to capture meaningful opportunities as China’s swine industry continues to modernize. These achievements position the Company to better serve the evolving needs of large-scale domestic customers while supporting continued expansion in selected international markets. Core Achievements in 2025: A Year of Strategic Execution and Innovation Over the past year, we focused on strengthening our innovation capabilities, advancing regulatory milestones, and building operational excellence to capture opportunities in an evolving industry landscape. What guided us through these efforts was our unwavering commitment to becoming a world-leading manufacturer that delivers reliable veterinary vaccines to customers around the world. Every patent filed, every regulatory approval earned, and every capability enhanced represents a deliberate investment in our future competitiveness and our ability to better serve our customers. 1. R&D Innovation and Regulatory Milestones 2. Advancing International Market Expansion 3.&n...

View stock analysis, news, and events for Zhengye Biotechnology Holding Limited